Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317547 | 0.76 | HTR6 (0.45) | CNR1HSD11B1SLC6A2SLC6A4SSTR4 | |
| SCHEMBL3317794 | 0.76 | CNR1 (0.46) | CNR1SSTR4CASR | |
| SCHEMBL2439245 | 0.74 | SSTR4 (0.58) | SSTR4CASR | |
| SCHEMBL15247598 | 0.73 | P2RX7 (0.49) | CNR1HSD11B1IDH1P2RX7 | |
| SCHEMBL12810174 | 0.73 | P2RX7 (0.44) | CNR1HSD11B1SLC6A4P2RX7HTR2A | |
| SCHEMBL2401012 | 0.73 | P2RX7 (0.44) | CNR1HSD11B1SLC6A4P2RX7HTR2A | |
| Hydrochloric Acid SCHEMBL2437871 | 0.73 | SSTR4 (0.56) | SSTR4CASR | |
| SCHEMBL4956360 | 0.72 | GAA (0.65) | SLC6A2SLC6A4HTR2BCASR | |
| Hydrochloric Acid SCHEMBL5718670 | 0.70 | ACP3 (0.42) | CNR1HSD11B1P2RX7 | |
| SCHEMBL7719646 | 0.69 | TDP1 (0.45) | SOS1IDH1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | CNR1 1/4885HSD11B1 823/4885CHRNB2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.